地西他滨治疗骨髓增生异常综合征(MDS)的疗效及其影响因素分析  

Therapeutic effect of DAC on MDS and its influencing factors

作　　者：何旭[1] 杨昆 胡银山 全凤琼[1] 马春蓉[1] HE Xu;YANG Kun;HU Yin-shan(Hematology Department,The Second ClinicalMedical College of North Sichuan Medical College,Nanchong Central Hospital,Nanchong 637000,China)

机构地区：[1]川北医学院第二临床医学院南充市中心医院血液内科

出　　处：《吉林医学》2019年第10期2258-2260,共3页Jilin Medical Journal

摘　　要：目的:探讨地西他滨(DAC)联合常规化疗治疗骨髓增生异常综合征(MDS)的疗效及对其影响因素。方法:选取50例MDS患者进行回顾性分析,根据治疗方案分为传统组25例(采用CAG/DA方案),研究组25例(采用DAC联合CAG/DA方案),对比两组的临床治疗效果,并进行影响因素分析。结果:研究组患者的总有效率72%高于对照组的40%,差异具有统计学意义(P<0.05);研究组和对照组的白细胞减少、血红蛋白(Hb)减少、血小板减少、肺部感染、肛周感染、尿路感染、肝功能损害、恶心呕吐、黏膜炎的发生率比较,差异均无统计学意义(P>0.05);50例MDS患者,共计获得有效28例,无效22例,进行分组分析,结果显示:治疗前患者的Hb水平、WHO分期、染色体核型对MDS患者治疗效果具有显著影响,差异有统计学意义(P<0.05)。结论:DAC联合常规化疗治疗MDS的疗效较好,不会增加患者的不良反应,对MDS疗效的影响因素除了治疗方案以外,还与患者的Hb、WHO分期、染色体核型有关。Objective To investigate the efficacy of capecitabine (DAC) combined with conventional chemotherapy in the treatment of myelodysplastic syndromes (MDS) and its influencing factors. Method A retrospective fifty patients with MDS were enrolled in our study.According to the treatment regimen,25 patients (using CAG / DA program) and 25 patients (using DAC Combined with CAG / DA program), compared the clinical efficacy of the two groups,and the influencing factors analysis. Results The total effective rate of the study group was 72.00%,which was higher than that of the control group (40.00%, P <0.05);There were no significant differences in the incidence of leukopenia,hemoglobin reduction,thrombocytopenia,pulmonary infection,perianal infection,urinary tract infection,liver function damage, nausea and vomiting,mucositis between the study group and the control group ( P >0.05);50 cases of MDS patients,a total of 28 cases were effective,ineffective in 22 cases,the group analysis,The results showed that Hb level,WHO stage and chromosome karyotype had a significant effect on the treatment of MDS patients before treatment ( P <0.05). Conclusion DAC combined with conventional chemotherapy for the treatment of MDS better,will not increase the adverse reactions of patients,the impact of MDS effects of the treatment program,but also with the patient′s Hb,WHO staging,chromosome karyotype.

关 键 词：地西他滨 骨髓增生异常综合征 疗效 影响因素 

分 类 号：R551.3[医药卫生—血液循环系统疾病]